CorMedix (CRMD) Stock: Is The Reverse Split An Opportunity?

CarMedix CRMD Stock News

CorMedix Inc. (NYSEAMERICAN: CRMD) is having a rough day in the market today, and for good reason. The company moved forward with a one for five reverse stock split. While these moves are cosmetic, not effecting percentage ownership, they tend to lead to declines as we’re seeing today. Nonetheless, these declines may represent an opportunity … Read more

Atossa Genetics (ATOS) Stock: Gaining On Institutional Review Board News

Atossa Therapeutics ATOS Stock News

Atossa Genetics Inc (NASDAQ: ATOS) is making a run for the top in the market this morning, and for good reason. The company announced a positive result from an Institutional Review Board (IRB) review. Of course, the news excited investors, pushing the stock for the top. Today, we’ll talk about: The IRB news; what we’re … Read more

Aldeyra Therapeutics (ALDX) Stock: Flying On Clinical Data

Aldeyra Therapeutics ALDX Stock News

Aldeyra Therapeutics Inc (NASDAQ: ALDX) is flying early on in the trading session this morning, and for good reason. The company announced positive late-stage clinical data, exciting investors and sending the stock screaming for the top. Today, we’ll talk about: The positive clinical data; what we’re seeing from ALDX stock as a result; and what … Read more

Biocept (BIOC) Stock: Climbing On Broadened Commercial Focus

Biocept BIOC Stock News

Biocept Inc (NASDAQ: BIOC) is having a great start to the trading session this morning, and for good reason. The company announced that it has broadened its commercial focus, exciting investors and sending the stock screaming for the top. Today, we’ll talk about: The news; what we’re seeing from BIOC stock as a result; and … Read more

Biogen (BIIB) Stock: Announces Buybacks After Painful Drop

Biogen BIIB Stock News

Biogen Inc (NASDAQ: BIIB) is making its way into the green this mroning after announcing a buyback program. The program comes after the company saw a painful drop in value after announcing the discontinuation of a clinical study. Today, we’ll talk about: The BIIB stock buyback program; what we’re seeing from the stock in the … Read more

Cyclacel Pharmaceuticals (CYCC) Stock: Gaining Big On Publication Validating CYC065

Cyclacel Pharmaceuticals CYCC Stock News

Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) is having an incredibly strong start to the trading session this morning, and for good reason. The company announced the publication of findings surrounding Cyclin E1 that further validates its work with its CYC065 treatment. Today, we’ll talk about: The publication; what we’re seeing from CYCC stock as a result; … Read more

OPKO Health (OPK) Stock: Climbing On Clinical Data

Opko Health OPK Stock News

OPKO Health Inc. (NASDAQ: OPK) is having an incredibly strong start to the trading session this morning, and for good reason. The company announced positive results from a phase 2 clinical trial, exciting investors who are pushing the stock for the top. Today, we’ll talk about: The clinical data; what we’re seeing from OPK stock … Read more